Home » Market News » DirectorsTalk Highlights » INTERVIEW: Northland Capital Vadim Alexandre on ImmuPhrama Plc Phase III trial update
Immupharma Plc

INTERVIEW: Northland Capital Vadim Alexandre on ImmuPhrama Plc Phase III trial update

Northland Capital Partners Head of research Vadim Alexandre talks to DirectorsTalk about the phase III trial update announced by Immupharma Plc (LON:IMM). Vadim talks us through the highlights and the keys points to take away from this update.

Vadim has over a decade of capital markets experience, specialising in the healthcare sector. He joins Northland from Daniel Stewart & Company plc, where he headed the research department and developed a leading healthcare franchise for the firm.

ImmuPharma Plc is a pharmaceutical development company listed since 2006 on AIM of the London Stock Exchange, focusing on developing novel medicines with high sales potential in specialist markets with serious unmet need. The company is led by a commercially focused Board and management team with extensive experience. Lupuzor (also referred to as Forigerimod, or P140) is ImmuPharma’s lead compound and a potential treatment for lupus (or Systemic Lupus Erythematosus), a chronic, potentially life-threatening auto-immune disease. Lupuzorhas a novel mechanism of action aimed at modulating the body’s immune system so that it does not attack healthy cells, and avoids causing adverse side effects.  It has the potential to halt the progression of the disease in a substantial proportion of patients.

Receive our exclusive interviews – Enter your email to stay up to date.

Disclaimer: Statements in this article should not be considered investment advice, which is best sought directly from a qualified professional.